Xilio Therapeutics (XLO) Change in Accured Expenses (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Change in Accured Expenses data on file, last reported at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 75.91% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 171.18% YoY), and the FY2025 full-year result was -$979000.0, up 36.55% from the prior year.
• Change in Accured Expenses fell to -$1.5 million in Q1 2026, from $928000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.6 million in Q2 2022 to a low of -$6.4 million in Q1 2025.
• A 5-year average of -$135176.5 and a median of $664000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses tumbled 929.33% in 2022 and jumped 1669.67% in 2025, its largest moves.
• Tracing XLO's Change in Accured Expenses over 5 years: stood at $1.5 million in 2022, then decreased by 24.91% to $1.1 million in 2023, then plunged by 107.71% to -$85000.0 in 2024, then surged by 1191.76% to $928000.0 in 2025, then plunged by 265.52% to -$1.5 million in 2026.
• Business Quant data shows XLO's Change in Accured Expenses at -$1.5 million in Q1 2026, $928000.0 in Q4 2025, and $3.3 million in Q3 2025.